1103506-80-4

Basic information

• Product Name: 4-(2-{3-[3-(3-Cyano-phenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}-pyrimidin-5-yloxymethyl)-piperidine-1-carbonic acid tert-butyl ester
• Synonyms: 4-(2-{3-[3-(3-Cyano-phenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}-pyrimidin-5-yloxymethyl)-piperidine-1-carbonic acid tert-butyl ester
• CAS NO: 1103506-80-4
• Molecular Weight: 578.671
• Mol File: 1103506-80-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(2-{3-[3-(3-Cyano-phenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}-pyrimidin-5-yloxymethyl)-piperidine-1-carbonic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-{3-[3-(3-Cyano-phenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}-pyrimidin-5-yloxymethyl)-piperidine-1-carbonic acid tert-butyl ester(1103506-80-4)
• EPA Substance Registry System: 4-(2-{3-[3-(3-Cyano-phenyl)-6-oxo-6H-pyridazin-1-ylmethyl]-phenyl}-pyrimidin-5-yloxymethyl)-piperidine-1-carbonic acid tert-butyl ester(1103506-80-4)

Safety Data

• Hazardous Substances Data: 1103506-80-4(Hazardous Substances Data)

Upstream product

• 1103506-79-1 3-{1-[3-(5-hydroxy-pyrimidin-2-yl)-benzyl]-6-oxo-1,6-dihydro-pyridazin-3-yl}-benzonitrile 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 

Downstream Products

• 1100598-32-0 (3-(1-(3-(5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl)benzyl)-1,6-dihydro-6-oxopyridazin-3-yl)benzonitrile) 

Relevant articles and documents

NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF

The present invention relates to hydrochloride solvates of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.